RNA-seq of 7 breast PDX models treated with Fulvestrant and AZD9833/camizestrant and collected at multiple timepoints
Oral selective estrogen receptor degraders (SERDs) could become the backbone endocrine therapy (ET) for estrogen receptor-positive (ER+) breast cancer, as they achieve greater inhibition of ER-driven cancers than current ETs and overcome key resistance mechanisms. This dataset was aimed at exploring the preclinical effects of the next-generation oral SERD camizestrant (AZD9833) on 7 PDX models. Mice were treated with fulvestrant or camizestrant for 4, 24, 48, 72 hours, with at least four replicates per condition.